31 июл. 2024 г. · April 5, 2024 Approval Letter - CARVYKTI · April 5, 2024 Statistical Review - CARVYKTI · December 21, 2023 Approval Letter - CARVYKTI ... |
5 апр. 2024 г. · We have approved your request received June 6, 2023, to supplement your Biologics. License Application (BLA) submitted under section 351(a) ... |
Apr 5, 2024, Approval FDA Approves Carvykti for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line ... |
11 апр. 2024 г. · Carvykti: FDA-approved for Treatment of RRMM After At Least One Prior Line of Therapy · Potential Period Away from MM Treatment as Early as First ... |
8 апр. 2024 г. · FDA Approves CARVYKTI® and ABECMA for Early Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma. April 08, 2024. |
30 мар. 2022 г. · The FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or ... |
15 мар. 2024 г. · CARVYKTI® received U.S. Food and Drug Administration approval in February 2022 for the treatment of adults with relapsed or refractory multiple ... |
28 авг. 2024 г. · This indication, for which the therapy was approved by the FDA in April 2024, is an expansion of the therapy's previous indication in the US, ... |
6 апр. 2024 г. · Carvykti (ciltacabtagene autoleucel) has gained FDA approval to treat patients with multiple myeloma (MM) earlier. |
| Novbeti > |
| Axtarisha Qayit Anarim.Az Anarim.Az Sayt Rehberliyi ile Elaqe Saytdan Istifade Qaydalari Anarim.Az 2004-2023 |